PTJ
KYMR icon

Paul Tudor Jones’s Kymera Therapeutics KYMR Stock Holding History

Paul Tudor Jones’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-32,162
Closed -$1.52M – 3289
2024
Q3 		$1.52M Buy
+32,162
New +$1.42M 0.01% 1373
2024
Q2 		– Sell
-46,373
Closed -$1.86M – 2564
2024
Q1 		$1.86M Buy
+46,373
New +$1.66M 0.01% 1052
2023
Q4 		– Sell
-27,296
Closed -$379K – 2631
2023
Q3 		$379K Sell
27,296
-24,926
-48% -$501K ﹤0.01% 1813
2023
Q2 		$1.2M Buy
52,222
+22,800
+77% +$653K 0.01% 1204
2023
Q1 		$872K Buy
29,422
+1,368
+5% +$44.1K 0.01% 1282
2022
Q4 		$700K Buy
28,054
+5,191
+23% +$138K 0.01% 1356
2022
Q3 		$498K Sell
22,863
-18,449
-45% -$486K 0.01% 1396
2022
Q2 		$813K Sell
41,312
-14,488
-26% -$338K 0.02% 998
2022
Q1 		$2.36M Buy
55,800
+30,683
+122% +$1.3M 0.06% 471
2021
Q4 		$1.59M Buy
+25,117
New +$1.46M 0.03% 754
2021
Q2 		– Sell
-5,542
Closed -$215K – 1769
2021
Q1 		$215K Sell
5,542
-10,511
-65% -$633K ﹤0.01% 1407
2020
Q4 		$995K Sell
16,053
-75,463
-82% -$3.68M 0.03% 704
2020
Q3 		$2.96M Buy
+91,516
New +$2.79M 0.13% 179

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Paul Tudor Jones's KYMR Position: Q4 2024 in Review

Paul Tudor Jones sold out of Kymera Therapeutics (KYMR) in Q4 2024, closing a stake of 32,162 shares — an estimated $1.52M sold.

Paul Tudor Jones first reported a position in KYMR in Q3 2020 and held it in 13 quarters. The position peaked at $2.96M in Q3 2020. 180 funds tracked by Wall St. Rank hold KYMR as of Q4 2024.

  • Paul Tudor Jones reported no remaining Kymera Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Paul Tudor Jones sold 32,162 Kymera Therapeutics shares in Q4 2024, an estimated $1.52M.
  • Paul Tudor Jones first reported a position in Kymera Therapeutics in Q3 2020 and held it in 13 quarters.
  • Paul Tudor Jones's Kymera Therapeutics position peaked at $2.96M in Q3 2020.
  • 180 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2024.

Based on Tudor Investment Corp's 13F filing for Q4 2024, filed 14 Feb 2025.